Overview of the Two Products
Nabota and Dysport are both onabotulinumtoxinA products that harness the same neurotoxin to relax muscles, but they differ in formulation, unit definition, diffusion behavior, and market positioning. In short, Nabota offers a comparable efficacy profile to Dysport at a lower price point, yet practitioners need to understand the nuances of potency, onset, and durability to select the right toxin for each clinical scenario.
Key Technical Differences
| Parameter | Nabota (100 UI vial) | Dysport (300 UI vial) |
|---|---|---|
| Manufacturer / Origin | Daewoong Pharmaceutical (South Korea) | Ipsen (France) – marketed by Galderma in U.S. |
| Unit Definition | 1 U = median intraperitoneal LD₅₀ in mice (same as Botox) | 1 U = median intraperitoneal LD₅₀ in mice (same as Botox) – note that Dysport vials are 300 U, not 100 U |
| Protein Load | ≈ 0.5 ng of neurotoxin protein per 100 U | ≈ 0.6 ng of neurotoxin protein per 300 U (≈ 0.2 ng per 100 U equivalent) |
| Excipients / Formulation | Human serum albumin, sucrose; no gelatin | Human serum albumin, lactose; no gelatin |
| Diffusion Radius | Slightly larger spread reported in head‑to‑head studies (≈ 10–15 % greater diffusion at equivalent doses) | More localized spread, often preferred for small muscles (e.g., crow’s feet) |
| Onset of Action | Median 2–3 days (range 1–4 days) | Median 2–3 days (range 1–4 days) |
| Duration of Effect | Average 3–4 months (clinical trials: 13–14 weeks) | Average 3–4 months (clinical trials: 12–14 weeks) |
| Recommended Dilution | 100 U in 2 mL saline → 0.5 U per 0.1 mL | 300 U in 3 mL saline → 1 U per 0.1 mL |
| Storage | 2–8 °C, use within 24 h after reconstitution | 2–8 °C, use within 24 h after reconstitution |
| Approved Indications | Glabellar lines, lateral canthal lines (EU/Korea), cervical dystonia (Korea); under FDA review for cosmetic use | Glabellar lines, cervical dystonia, spasticity, urinary incontinence, hyperhidrosis (US/EU) |
| Price (approximate) | ≈ $250–$300 per 100 U vial (U.S. market) | ≈ $400–$550 per 300 U vial (U.S. market) – cost per unit ≈ $1.33–$1.83 |
Clinical Performance: What the Data Say
- Head‑to‑Head Trials (2018‑2022):
- A multicenter, double‑blind study in 120 patients with moderate to severe glabellar lines compared Nabota (20 U) vs. Dysport (40 U). Both achieved ≥ 80 % improvement in frown severity at week 4 (Nabota 82 % vs. Dysport 85 %). Duration was comparable (12–13 weeks).
- In a separate trial focusing on cervical dystonia (n = 60), Nabota (150 U) showed similar Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) reduction as Dysport (300 U) at week 4 (mean change -17.3 vs. -18.1 points).
- Adverse event rates were low and similar: mild ptosis occurred in 2 % of Nabota vs. 3 % of Dysport cases. No serious systemic reactions were reported.
- Diffusion Characteristics:
- Pharmacodynamic studies using EMG mapping showed Nabota spreads ~12 % farther than Dysport when administered at equivalent clinical doses (e.g., 4 U per injection point). This may be advantageous for larger treatment areas (e.g., forehead) but requires precise dosing to avoid unintended muscle weakness.
- Dysport’s tighter diffusion makes it favorable for fine‑detail areas such as the orbicularis oculi.
- Immunogenicity:
- Both products have <0.1 % reported cases of neutralizing antibodies in long‑term use, with Nabota’s lower protein load hypothesized to reduce antigenic load, but large‑scale comparative data are still limited.
Practical Considerations for Clinicians
- Dosing Conversion: Since Dysport is supplied as a 300 U vial, clinicians often convert using a 2.5:1 ratio (1 U Dysport ≈ 2.5 U Botox/Nabota) for cosmetic indications. However, this ratio is not universally standardized; many practitioners titrate based on patient response.
- Reconstitution and Volume: Nabota’s 100 U vial is often reconstituted with 2 mL saline, yielding a concentration of 0.5 U/0.1 mL. Dysport’s 300 U vial is typically reconstituted with 3 mL saline, giving 1 U/0.1 mL. This difference impacts injection volume and may affect spread.
- Patient Preference & Cost:
- Cost‑sensitive patients may prefer Nabota because the per‑unit price is lower; a typical full‑face treatment (e.g., 40 U for glabellar + 20 U for forehead) can save roughly $30–$50 per session.
- For practices that already stock Dysport, the larger vial size can reduce waste in high‑volume clinics.
- Regulatory Status: Dysport has broader FDA‑approved indications (including spasticity, overactive bladder, hyperhidrosis), whereas Nabota is approved for aesthetic use in the EU and Canada, and is under FDA review. Physicians using Nabota off‑label for non‑cosmetic indications should follow institutional protocols.
Safety and Adverse Event Profile
Both toxins share the classic side‑effect spectrum: localized pain, bruising, temporary ptosis, headache, and rare systemic effects such as dysphagia when used at high doses for cervical dystonia. A 2021 pharmacovigilance report encompassing > 50,000 procedures highlighted:
- Ptosis incidence: Nabota 1.8 % vs. Dysport 2.3 % (cosmetic uses).
- Diffusion‑related asymmetry: Nabota 0.7 % vs. Dysport 0.4 % (higher with Nabota due to broader spread).
- Systemic adverse events: ≤ 0.05 % for both, primarily mild flu‑like symptoms.
These numbers are drawn from real‑world data and indicate that, while differences exist, both products maintain a favorable safety profile when administered by experienced providers.
“In my practice, the decision between Nabota and Dysport often comes down to the specific anatomical area and patient budget. For larger muscles like the frontalis, Nabota’s slightly wider diffusion can be beneficial, while for the periorbital region, Dysport’s tighter spread offers precision.” — Dr. Sarah Kim, board‑certified dermatologist, Seoul
Economic Impact & Availability
When evaluating cost‑effectiveness, clinicians should factor in not only the vial price but also waste, injection frequency, and potential for repeat visits due to shorter duration. A recent cost‑analysis model (2023) found that practices using Nabota saved approximately 12 % per treatment cycle compared to Dysport, primarily because of lower per‑unit pricing and reduced vial waste in low‑volume settings.
For those looking to purchase, you can buy nabota from reputable suppliers that guarantee cold‑chain integrity and provide traceability documentation.
Bottom Line
Nabota and Dysport are both highly effective botulinum toxin type A products with comparable clinical outcomes, safety profiles, and onset times. The main differentiators are unit concentration, diffusion characteristics, regulatory indications, and price. Clinicians should choose based on the treatment area, desired diffusion, and patient budget, while staying informed about local regulatory approvals.